Select pharma stocks were trading higher on the BSE, as maintaining a neutral outlook for the pharmaceuticals sector for FY25, credit rating agency, India Ratings and Research (Ind-Ra) in its latest report is expecting pharmaceuticals companies to continue to benefit from growth in the domestic as well as export markets, while maintaining healthy EBITDA margins led by a moderation in the price erosion in the US generics business, softening of input costs, and high-value product launches in the US generic market.
Aurobindo Pharma is currently trading at Rs. 1012.15, up by 22.75 points or 2.30% from its previous closing of Rs. 989.40 on the BSE.
Alembic Pharmaceuticals is currently trading at Rs. 949.10, up by 14.75 points or 1.58% from its previous closing of Rs. 934.35 on the BSE.
Glenmark Pharmaceuticals is currently trading at Rs. 928.65, up by 9.20 points or 1.00% from its previous closing of Rs. 919.45 on the BSE.
According to report named ‘FY25 Pharmaceuticals Outlook: Moving Up the Value Chain; Sustainable Margins in Sight’, the Indian pharmaceuticals market (IPM) is likely to grow 8%-9% year on year (yoy) in FY25 (FY24: 6%-7% yoy; FY23: 9.3% yoy). It further expects its US-focused pharma issuers to remain stable or report mid-to single-digit revenue growth in FY25 (FY23: 7.2% yoy; 9MFY24: 18.5% yoy) on account of lack of revenue from one-off products. Hence, the overall proportion of sales from the US is likely to remain stable.
The report further noted that the active pharmaceuticals ingredients (API) business of Ind-Ra selected companies is expected to report high single-digit growth in FY25 due to a demand uptick. The overall revenue growth for them is also expected at around 9% yoy while maintaining healthy EBITDA margin performance (around 22%) in FY25. It also said that there has recently been a wave of M&A activity in the domestic formulations space, which is likely to continue.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.50 |
| Dr. Reddys Lab | 1342.45 |
| Cipla | 1472.45 |
| Lupin | 2147.55 |
| Zydus Lifesciences | 973.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
